Treatment of Early-Stage Non-Small Cell Lung Cancer
Immunotherapy, which has demonstrated benefits in advanced and metastatic settings, is moving into early non-small cell lung cancer treatment, expanding options for patients with resected or resectable early-stage non-small cell lung cancer. This rapid evolution of the early NSCLC treatment landscape, while exciting, has created clinical challenges as health care providers struggle with translating these clinical trial results into real-world clinical practices in the adjuvant and neoadjuvant settings. This educational initiative establishes impactful small group interactions among oncology care providers that will, through a variety of collaborative educational experiences, help them optimize the care of their patients with early-stage NSCLC.<br> <img src="https://s3.amazonaws.com/media.gathered.com/author/medicallogix/jhu-logo.jpg" width="200" alt="John Hopkins Medicine Logo" title="John Hopkins Medicine Logo">
Turning Complexity into Clarity in AML
Acute myeloid leukemia (AML) continues to be the most common acute leukemia in adults, with an incidence of 5.5 cases per 100,000 persons annually. As such, more education is needed on key topics including use of induction therapy in the non-elderly population, treating suboptimal response to induction therapy, best practices for measurable (or minimal) residual disease assessment, and proper use of maintenance therapy..The goal of this educational curriculum, Turning Complexity into Clarity in AML, is to establish impactful small group interactions between members of the AML care team that will, through a variety of collaborative educational experiences, help them in learning and sharing best practices that will improve outcomes for patients with AML.<br> <img src="https://s3.amazonaws.com/media.gathered.com/author/medicallogix/montefiore-einstein.png" width="230" alt="Montefiore Einstein Logo" title="Montefiore Einstein Logo">
